- Home
- OMCC vs ITRM Comparison
OMCC vs ITRM Comparison
Compare OMCC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- ITRM
- Stock Information
- Founded
- OMCC 1985
- ITRM 2015
- Country
- OMCC United States
- ITRM Ireland
- Employees
- OMCC N/A
- ITRM N/A
- Industry
- OMCC
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- OMCC
- ITRM Health Care
- Exchange
- OMCC NYSE
- ITRM Nasdaq
- Market Cap
- OMCC 43.4M
- ITRM 49.5M
- IPO Year
- OMCC N/A
- ITRM 2018
- Fundamental
- Price
- OMCC $6.05
- ITRM $1.77
- Analyst Decision
- OMCC
- ITRM Strong Buy
- Analyst Count
- OMCC 0
- ITRM 1
- Target Price
- OMCC N/A
- ITRM $5.00
- AVG Volume (30 Days)
- OMCC 17.8K
- ITRM 1.5M
- Earning Date
- OMCC 02-11-2025
- ITRM 11-14-2024
- Dividend Yield
- OMCC N/A
- ITRM N/A
- EPS Growth
- OMCC N/A
- ITRM N/A
- EPS
- OMCC N/A
- ITRM N/A
- Revenue
- OMCC $22,181,000.00
- ITRM N/A
- Revenue This Year
- OMCC N/A
- ITRM N/A
- Revenue Next Year
- OMCC N/A
- ITRM N/A
- P/E Ratio
- OMCC N/A
- ITRM N/A
- Revenue Growth
- OMCC N/A
- ITRM N/A
- 52 Week Low
- OMCC $5.29
- ITRM $0.81
- 52 Week High
- OMCC $7.55
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- ITRM 46.56
- Support Level
- OMCC N/A
- ITRM $1.63
- Resistance Level
- OMCC N/A
- ITRM $1.95
- Average True Range (ATR)
- OMCC 0.00
- ITRM 0.27
- MACD
- OMCC 0.00
- ITRM -0.10
- Stochastic Oscillator
- OMCC 0.00
- ITRM 10.39
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.